^
    7d
    Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Antitumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate Alone and in Combination With Darolutamide, in Patients With Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P1, N=63, Completed, Bayer | Active, not recruiting --> Completed
    Trial completion • Combination therapy • Metastases
    |
    Nubeqa (darolutamide) • pelgifatamab corixetan (BAY 2315497)
    14d
    MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma (clinicaltrials.gov)
    P1/2, N=264, Recruiting, Perspective Therapeutics | Trial completion date: Jun 2027 --> Dec 2029 | Trial primary completion date: Jun 2025 --> Dec 2027
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    Opdivo (nivolumab) • VMT-01
    18d
    CR108817: A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer (clinicaltrials.gov)
    P1, N=111, Recruiting, Janssen Research & Development, LLC | Trial primary completion date: Dec 2025 --> Feb 2028
    Trial primary completion date • Metastases
    |
    JNJ-6420
    18d
    The Radium-select Study (clinicaltrials.gov)
    P=N/A, N=60, Not yet recruiting, The Netherlands Cancer Institute
    New trial
    |
    Xofigo (radium Ra-223 dichloride)
    30d
    Phase I/II Trial of Pembrolizumab and Androgen-receptor Pathway Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P1/2, N=76, Recruiting, Weill Medical College of Cornell University | Suspended --> Recruiting
    Enrollment open • Metastases
    |
    Keytruda (pembrolizumab) • Xtandi (enzalutamide capsule) • Ac-225 rosopatamab tetraxetan (CONV01-α)
    1m
    CR108817: A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer (clinicaltrials.gov)
    P1, N=111, Recruiting, Janssen Research & Development, LLC | Trial completion date: Jan 2026 --> Aug 2028
    Trial completion date
    |
    JNJ-6420
    1m
    Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone Metastases (clinicaltrials.gov)
    P1, N=8, Terminated, Bayer | Phase classification: P1/2 --> P1
    Phase classification
    |
    Keytruda (pembrolizumab) • Xofigo (radium Ra-223 dichloride)
    1m
    Biomarkers of bone metabolism in [223Ra] RaCl2 therapy - association with extent of disease and prediction of overall survival. (PubMed, EJNMMI Res)
    BMM are significantly associated with scintigraphic extent of skeletal disease and OS in patients with mCRPC. Particularly, the bone resorption marker CTX-MMP is a promising surrogate marker for prediction of outcome in patients receiving Radium-223 therapy and could potentially improve selection of patients for therapy and assessment of response.
    Journal
    |
    TNFRSF11B (Tumor necrosis factor receptor superfamily member 11B)
    |
    Xofigo (radium Ra-223 dichloride)
    1m
    (SEEtoTREAT): SPECT Imaging for Pharmacokinetics and dosimEtry Towards TREATment Optimization (clinicaltrials.gov)
    P=N/A, N=80, Not yet recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Initiation date: Sep 2024 --> Dec 2024
    Trial initiation date
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan) • Lutathera (lutetium Lu 177 dotatate) • Xofigo (radium Ra-223 dichloride)
    2ms
    MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma (clinicaltrials.gov)
    P1/2, N=264, Recruiting, Perspective Therapeutics | N=52 --> 264
    Enrollment change • Combination therapy • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    Opdivo (nivolumab) • VMT-01
    2ms
    RAPSON: Sequencing of Radium-223 and Docetaxel in Symptomatic Bone-only Metastatic Castration-resistant Prostate Cancer (clinicaltrials.gov)
    P2, N=70, Active, not recruiting, Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori | Recruiting --> Active, not recruiting
    Enrollment closed • Metastases
    |
    docetaxel • prednisone • Xofigo (radium Ra-223 dichloride)
    2ms
    Re-treatment 225Ac-J591 for mCRPC (clinicaltrials.gov)
    P1, N=6, Active, not recruiting, Weill Medical College of Cornell University | Recruiting --> Active, not recruiting | N=18 --> 6
    Enrollment closed • Enrollment change
    |
    Ac-225 rosopatamab tetraxetan (CONV01-α)
    2ms
    TRACY-1: Trial of 225Ac-DOTATATE (RYZ101) Alone and with Pembrolizumab in Subjects with ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs (clinicaltrials.gov)
    P1/2, N=172, Recruiting, RayzeBio, Inc.
    New P1/2 trial • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • Actinium-225 DOTATATE (RYZ101)
    2ms
    ACCEL: [Ac-225]-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P1, N=142, Recruiting, POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company | N=48 --> 142
    Enrollment change • Metastases
    3ms
    ACTION-1: Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy (clinicaltrials.gov)
    P3, N=288, Recruiting, RayzeBio, Inc. | Active, not recruiting --> Recruiting
    Enrollment open • Metastases
    |
    SSTR (Somatostatin Receptor)
    |
    sunitinib • everolimus • Actinium-225 DOTATATE (RYZ101)
    3ms
    212-Pb-VMT: Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors (clinicaltrials.gov)
    P1/2, N=280, Recruiting, Perspective Therapeutics | N=52 --> 280 | Trial completion date: Jan 2028 --> Dec 2029 | Trial primary completion date: Sep 2026 --> Nov 2029
    Enrollment change • Trial completion date • Trial primary completion date • Metastases
    |
    SSTR (Somatostatin Receptor) • CD4 (CD4 Molecule) • SSTR2 (Somatostatin Receptor 2)
    |
    VMT-𝛼-NET
    3ms
    225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome (clinicaltrials.gov)
    P1, N=15, Not yet recruiting, City of Hope Medical Center | Initiation date: Jun 2024 --> Oct 2024
    Trial initiation date
    |
    Darzalex (daratumumab) • sirolimus • melphalan • fludarabine IV
    4ms
    Phase I/II Trial of Pembrolizumab and Androgen-receptor Pathway Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P1/2, N=76, Suspended, Weill Medical College of Cornell University | Recruiting --> Suspended | Trial primary completion date: Jun 2025 --> Jun 2026
    Trial suspension • Trial primary completion date • Metastases
    |
    Keytruda (pembrolizumab) • Xtandi (enzalutamide capsule) • Ac-225 rosopatamab tetraxetan (CONV01-α)
    4ms
    Fractionated and Multiple Dose 225Ac-J591 for Progressive mCRPC (clinicaltrials.gov)
    P1/2, N=105, Suspended, Weill Medical College of Cornell University | Recruiting --> Suspended
    Trial suspension • Metastases
    |
    Ac-225 rosopatamab tetraxetan (CONV01-α)
    4ms
    Phase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Castration Resistant Prostate Cancer (TheraPb - Phase I/II Study). (clinicaltrials.gov)
    P1/2, N=100, Recruiting, AdvanCell Isotopes Pty Limited | N=18 --> 100 | Trial completion date: Jun 2024 --> Dec 2029 | Trial primary completion date: Jun 2024 --> Dec 2027
    Enrollment change • Trial completion date • Trial primary completion date • Metastases
    4ms
    Phase I/II 225Ac-J591 Plus 177Lu-PSMA-I&T for Progressive Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P1/2, N=48, Suspended, Weill Medical College of Cornell University | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial primary completion date • Metastases
    |
    lutetium zadavotide guraxetan (PNT2002) • Ac-225 rosopatamab tetraxetan (CONV01-α)
    4ms
    Lead-203 VMT-α-Neuroendocrine Tumor Scintigraphy: A Promising Theranostics Agent. (PubMed, Indian J Nucl Med)
    As Pb-203 presents an accurate diagnostic surrogate to Pb-212, imaging with Pb-203-labelled peptides can be an important prerequisite to assess the feasibility of TAT with Pb-212-labelled agents. Here, we present the imaging data of a patient with metastatic NET with Pb-203 VMT-α-NET, a somatostatin receptor targeting agent, and demonstrate the matching distribution of Pb-203 VMT-α-NET with Ga-68 DOTANOC.
    Journal
    |
    SSTR (Somatostatin Receptor)
    |
    VMT-𝛼-NET
    5ms
    A Phase I/II, Open-label, Multi-center Study of [225Ac]Ac-PSMA-R2 in Men With PSMA-positive Prostate Cancer With or Without Prior 177Lu-PSMA Radioligand Therapy. (clinicaltrials.gov)
    P1/2, N=200, Recruiting, Novartis Pharmaceuticals | Trial completion date: Aug 2026 --> Oct 2027
    Trial completion date • Metastases
    5ms
    Lintuzumab-Ac225 in Combination With Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=26, Completed, Medical College of Wisconsin | Active, not recruiting --> Completed | Trial completion date: Oct 2024 --> May 2024
    Trial completion • Trial completion date • Combination therapy
    |
    cytarabine • mitoxantrone • Actimab-A (lintuzumab-Ac225) • Depocyte (liposomal cytarabine)
    6ms
    Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC (clinicaltrials.gov)
    P1, N=31, Recruiting, RayzeBio, Inc. | Trial primary completion date: Apr 2024 --> Mar 2025
    Trial primary completion date • Combination therapy
    |
    PD-L1 (Programmed death ligand 1) • SSTR (Somatostatin Receptor)
    |
    Tecentriq (atezolizumab) • carboplatin • etoposide IV • Actinium-225 DOTATATE (RYZ101)
    6ms
    ALPHAMEDIX02: Targeted Alpha-emitter Therapy of PRRT Naïve and Previous PRRT Neuroendocrine Tumor Patients (clinicaltrials.gov)
    P2, N=69, Active, not recruiting, Radiomedix, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    SSTR (Somatostatin Receptor)
    |
    AlphaMedix (ORM-2110)
    6ms
    Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy (clinicaltrials.gov)
    P1/2, N=53, Not yet recruiting, National Cancer Institute (NCI)
    New P1/2 trial • Metastases
    |
    VMT-𝛼-NET
    6ms
    AcTRESS: A Phase I Study to Assess the Tolerability of 225Ac-DOTATATE in Patients With Refractory and Relapsing Multiple Myeloma Expressing Somatostatin Receptors (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, Jules Bordet Institute
    New P1 trial
    |
    Actinium-225 DOTATATE (RYZ101)
    6ms
    AlphaBreak: FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) (clinicaltrials.gov)
    P2/3, N=60, Recruiting, Fusion Pharmaceuticals Inc.
    New P2/3 trial • Metastases
    |
    FPI-2265
    7ms
    ACTION-1: Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy (clinicaltrials.gov)
    P3, N=288, Active, not recruiting, RayzeBio, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed • Metastases
    |
    SSTR (Somatostatin Receptor)
    |
    sunitinib • everolimus • Actinium-225 DOTATATE (RYZ101) • Somatuline Depot (lanreotide prolonged-release subcutaneous) • octreotide acetate
    7ms
    A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors (clinicaltrials.gov)
    P1, N=24, Active, not recruiting, David Bushnell | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    VMT-𝛼-NET
    7ms
    ACCEL: [Ac-225]-PSMA-62 Trial in Biochemically Recurrent and Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P1, N=48, Recruiting, POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    7ms
    A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours (clinicaltrials.gov)
    P1, N=110, Recruiting, Fusion Pharmaceuticals Inc. | Initiation date: Feb 2024 --> Jun 2024
    Trial initiation date • Metastases
    7ms
    Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC (clinicaltrials.gov)
    P1, N=31, Recruiting, RayzeBio, Inc. | Phase classification: P1b --> P1
    Phase classification • Combination therapy
    |
    PD-L1 (Programmed death ligand 1) • SSTR (Somatostatin Receptor)
    |
    SSTR positive
    |
    Tecentriq (atezolizumab) • carboplatin • etoposide IV • Actinium-225 DOTATATE (RYZ101)
    8ms
    64Cu-TLX592 Phase I Safety, PK, Biodistribution and Dosimetry Study (CUPID Study) (clinicaltrials.gov)
    P1, N=14, Completed, Telix International Pty Ltd | Recruiting --> Completed | Trial completion date: Apr 2023 --> Jan 2024 | Trial primary completion date: Apr 2023 --> Dec 2023
    Trial completion • Trial completion date • Trial primary completion date
    |
    FOLH1 expression
    8ms
    Targeted Alpha Particle Radiotherapy for Metastatic Uveal Melanoma (clinicaltrials.gov)
    P1, N=16, Recruiting, Modulation Therapeutics, Inc. | Trial primary completion date: Dec 2023 --> Apr 2025
    Trial primary completion date • Metastases
    8ms
    Actinium 225 Labeled Anti-CEA Antibody (Ac225-DOTA-M5A) for the Treatment of CEA Producing Advanced or Metastatic Cancers (clinicaltrials.gov)
    P1, N=20, Recruiting, City of Hope Medical Center | Trial completion date: Mar 2024 --> Aug 2025 | Trial primary completion date: Mar 2024 --> Aug 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    CEACAM5 positive
    9ms
    A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer (clinicaltrials.gov)
    P1, N=111, Recruiting, Janssen Research & Development, LLC | Trial completion date: Sep 2025 --> Dec 2025 | Trial primary completion date: Mar 2025 --> Dec 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    JNJ-6420
    9ms
    225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome (clinicaltrials.gov)
    P1, N=15, Not yet recruiting, City of Hope Medical Center
    New P1 trial
    |
    Darzalex (daratumumab) • sirolimus • melphalan • fludarabine IV
    9ms
    Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer (clinicaltrials.gov)
    P1, N=60, Recruiting, Endocyte | Trial completion date: Mar 2026 --> Jan 2027 | Trial primary completion date: Mar 2026 --> Jan 2027
    Trial completion date • Trial primary completion date
    |
    abiraterone acetate • Pluvicto (lutetium Lu 177 vipivotide tetraxetan) • AAA817
    9ms
    Radioimmunotherapy (211At-OKT10-B10) and Chemotherapy (Melphalan) Before Stem Cell Transplantation for the Treatment of Multiple Myeloma (clinicaltrials.gov)
    P1, N=0, Withdrawn, Fred Hutchinson Cancer Center | N=30 --> 0 | Recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    CD34 (CD34 molecule)
    |
    melphalan • 211At-OKT10-B10
    10ms
    NCI-2022-03039: Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=15, Recruiting, City of Hope Medical Center | Suspended --> Recruiting
    Enrollment open
    |
    CD38 expression
    |
    Darzalex (daratumumab)